EUCTR2016-004987-21-GB进行中（未招募）1 期
An open-label, multi-center, dose-escalation and expansion study to evaluate the safety and efficacy of ONO-7579 in patients with advanced solid tumors/ NTRK gene fusion positive advanced solid tumors - ONTRK
Ono Pharmaceutical Co., Ltd.0 个研究点目标入组 65 人开始时间: 2017年4月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Common criteria for Part A and B:
- •1. Male or female aged at least 18 years or older, at the time of signing the informed consent form.
- •2. ECOG performance status = 2.
- •3. Life expectancy of at least 3 months.
- •4. Patients must have a measurable disease, according to RECIST 1.1 or RANO criteria for Glioma.
- •5. Patients must have received at least one prior line of therapy appropriate for their tumor type and stage of disease. For glioma, patient must have received at least one prior treatment with radiotherapy and Temozolomide. Prior treatment of any Trk inhibitor(s) is not an exclusion.
- •6. Adequate hematologic, hepatic and renal function.
- •7. Women of childbearing potential must have a negative serum pregnancy test documented within 14 days prior to enrollment, and must agree to use two adequate methods of contraception from Day 1 of the study until 3 months after the end of treatment.
- •8. Women of non-childbearing potential, defined as females with a documented history of a clinically recognized procedure (e.g. hysterectomy, tubal ligation, bilateral salpingo-/oophorectomy); or postmenopausal.
- •Additional Criterion for Part A only
- •1. Patients with histologically/cytologically confirmed advanced solid tumors, and documented tumor progression for whom no further standard anticancer treatment is available.
- •Additional Criteria for Part B only
- •1. Patients with histologically/cytologically confirmed advanced solid tumors and documented tumor progression for whom no further standard anti-cancer treatment exists or where, in the opinion of the investigator, the existing standard anti-cancer treatment options available are not expected to provide a reasonable benefit to the patient.
- •2. Patient requires treatment with systemic anti-cancer therapy, in the opinion of the investigator.
- •3. Patients must have NTRK1, NTRK2 or NTRK3 gene fusion confirmed locally prior to first dose.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Common Criteria of Part A and B:
- •1. Radiotherapy within two weeks prior to study entry.
- •2. Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of study treatment.
- •3. Spinal cord compression or brain metastases unless treated and radiologically stable for >6 weeks post treatment and not requiring steroids for at least 4 weeks prior to start of study treatment.
- •4. As judged by the Investigator, any evidence of severe or uncontrolled psychiatric disease or systemic diseases, including history of suicide attempt or current suicidal ideation or behavior, active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
- •5. Clinically significant cardiovascular disease, including:
- •- History of myocardial infarction, acute coronary syndromes (including unstable angina), or coronary angioplasty/stenting/bypass grafting within the past 6 months.
- •- History of Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
- •- Severe cardiac arrhythmia requiring medication or other severe conduction abnormalities (e.g. clinically significant QT prolongation or Torsade de pointes)
- •- Uncontrolled hypertension
- •- Clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, or cardiomyopathy
- •6. QT prolongation defined as a QTcF interval >470 msec or other significant ECG abnormalities including 2nd degree (type II) or 3rd degree AV block or bradycardia (ventricular rate <50 beats/min) on 12-lead ECG at screening.
- •7. Serious concurrent medical conditions, including serious active infection, in the opinion of the investigator.
- •10. Female patients who are pregnant or breast-feeding.
研究者
相似试验
已完成
1 期
A study of the safety, pharmacokinetics, and therapeutic activity of cibisatamab in combination with atezolizumab in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumorsSolid tumorsCancerISRCTN16358704Genentech, Inc228
已完成
不适用
An open-label, multicenter, dose escalation and expansion Phase Ib study to evaluate the safety, pharmacokinetics and therapeutic activity of RO6958688 in combination with atezolizumab in patients with locally advanced and/or metastatic CEA-positive solid tumorssolide tumorensolid tumorsCancerNL-OMON47345Roche Nederland B.V.15
进行中（未招募）
不适用
An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.Patients with relapsed CD20+ indolent NHL will be enrolled (Relapsed defined asrelapsed indolent lymphoma with documented history of response [CR, CRu, or PR) of=6 months in duration from the completion of last rituximab containing regimen at some point in a patients treatment history).MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2008-003460-19-ATF.Hoffmann-La Roche220
进行中（未招募）
1 期
An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.Patients with relapsed CD20+ indolent NHL will be enrolled (Relapsed defined asrelapsed indolent lymphoma with documented history of response [CR, CRu, or PR) of=6 months in duration from the completion of last rituximab containing regimen at some point in a patients treatment history).MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2008-003460-19-BEF.Hoffmann-La Roche220
进行中（未招募）
不适用
An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.Patients with relapsed CD20+ indolent NHL will be enrolled (Relapsed defined asrelapsed indolent lymphoma with documented history of response [CR, CRu, or PR) of=6 months in duration from the completion of last rituximab containing regimen at some point in a patients treatment history).MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2008-003460-19-DKF.Hoffmann-La Roche220